new COX-2 inhibitor called Bextra (valdecoxib)
January 2002
You'll see a new COX-2 inhibitor called Bextra (valdecoxib).
It'll be co-marketed by Pharmacia and Pfizer...the same companies that market Celebrex (celecoxib).
Bextra is approved for osteoarthritis...rheumatoid arthritis...and dysmenorrhea. It's NOT approved yet for acute pain...but it probably will be after the company submits additional studies to the FDA.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote